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Abstract
Background: Mutations in the three-prime repair exonuclease 1 (TREX1) gene
have been associated with neurological diseases, including Retinal Vasculopathy
with Cerebral Leukoencephalopathy (RVCL). However, the endogenous expression
of TREX1 in human brain has not been studied. Methods: We produced a
rabbit polyclonal antibody (pAb) to TREX1 to characterize TREX1 by Western
blotting (WB) of cell lysates from normal controls and subjects carrying an RVCL
frame-shift mutation. Dual staining was performed to determine cell types expressing TREX1 in human brain tissue. TREX1 distribution in human brain was
further evaluated by immunohistochemical analyses of formalin-fixed, paraffinembedded samples from normal controls and patients with RVCL and ischemic
stroke. Results: After validating the specificity of our anti-TREX1 rabbit pAb,
WB analysis was utilized to detect the endogenous wild-type and frame-shift
mutant of TREX1 in cell lysates. Dual staining in human brain tissues from
patients with RVCL and normal controls localized TREX1 to a subset of microglia and macrophages. Quantification of immunohistochemical staining of the
cerebral cortex revealed that TREX1+ microglia were primarily in the gray matter
of normal controls (22.7 ± 5.1% and 5.5 ± 1.9% of Iba1+ microglia in gray and
white matter, respectively) and commonly in association with the microvasculature.
In contrast, in subjects with RVCL, the TREX1+ microglia were predominantly
located in the white matter of normal appearing cerebral cortex (11.8 ± 3.1%
and 38.9 ± 5.8% of Iba1+ microglia in gray and white matter, respectively). The
number of TREX1+ microglia was increased in ischemic brain lesions in central
nervous system of RVCL and stroke patients. Conclusions: TREX1 is expressed
by a subset of microglia in normal human brain, often in close proximity to the
microvasculature, and increases in the setting of ischemic lesions. These findings
suggest a role for TREX1+ microglia in vessel homeostasis and response to ischemic
injury.

INTRODUCTION
The autosomal dominant disease Retinal Vasculopathy with
Cerebral Leukoencephalopathy (RVCL) is characterized by
a systemic vasculopathy and encompasses the disorders
806

reported separately as Cerebroretinal Vasculopathy (CRV),
Hereditary Vascular Retinopathy (HVR), and Hereditary
Endotheliopathy with Retinopathy, Nephropathy, and Stroke
(HERNS). (6,11,24,26,30) RVCL is 100% penetrant by middleage when symptoms first develop. Visual defects due to
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peri-foveal capillary drop-out are typically followed by focal
and global neurological deficits as well as cognitive decline
due to white matter lesions in the cerebral hemispheres and
cerebellum. Neuroimaging from patients with RVCL shows
punctate, hyperintense lesions in almost all affected patients
with the majority also developing rim-enhancing mass lesions,
often associated with edema, as the disease progressed. (26)
Although the retina and white matter are most prominently
affected, other organs including the liver and kidney show
histopathological changes attributable to small vessel disease.
All patients endure an early death from neurological decline
due to progressive white matter lesions. The vasculopathy
is characterized by vascular wall thickening, multilaminated
basement membranes, and luminal narrowing that can progress to complete obliteration. The decrease in blood flow
results in ischemic necrosis and symptomatology, particularly
in the retina and white matter.
This devastating disease is caused by frame-shift mutations in TREX1, the three prime repair exonuclease 1,
that result in loss of its carboxy-tail. A truncated protein
is synthesized and secreted but is lacking the site for
its attachment to the endoplasmic reticulum (8,33).
Consequently, the protein becomes mislocated, being
observed in the cytoplasm and nucleus (24). While 14
different frame-shift mutations have been identified, the
most common is the V235fs seen in 13 unrelated kindreds. (26,31) All of the RVCL-associated mutations lead
to a functional exonuclease distributed diffusely in the
cytoplasm and nucleus instead of being anchored to the
endoplasmic reticulum (ER) like the wild-type
protein.(24)
In a prior report (Supplementary Table 3) (26), we
described 11 families in carrying five different mutations
(6/11 V235fs and 2/11 T249fs). By history and genetic
analyses, these families were not related (26). The results
are most consistent with the mutations being independent events with a relative “hot spot” at V235fs site. Since
publication of this article in 2016, we have now identified
(as of 04/01/18—M.K. Liszewski and J.P. Atkinson,
unpublished data) a total of 26 families worldwide in
which 13 carry the V235fs variant and 13 others have
fs variants corresponding to amino acid positions from
236 to 310 in the mature TREX1 protein. Most of the
families are of European origin including two of
Ashkenazi-Jewish ethnicity and one family of Chinese
background in Taiwan.
With respect to the types of mutations in RVCL compared to those in AGS, SLE, and FCL, the RVCL mutations are frame-shift mutations in the tail, while those in
AGS, SLE, and FCL are mostly missense or nonsense
and primarily in the enzymatic amino-terminal portion
of the protein. For readers interested in the various mutations in these other diseases, we refer the reader to two
recent reviews.(14,26,33)
The physiologic role of TREX1 is incompletely understood but recent studies have supported a role in clearing
single stranded DNA (ssDNA) derived from endogenous
retroelements.(29,35) In the absence of functional TREX1,
ssDNA accumulates and triggers an antiviral state with
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the induction of interferon (IFN) stimulated genes.(5) The
knock out mouse develops an inflammatory myocarditis
resulting in death at 2–6 months.(19,29) As such, TREX1
is thought to play a physiologic role in preventing
autoimmunity.
These findings are relevant for three other human
diseases associated with TREX1 mutations, Aicardi–
Gouitères syndrome (AGS), systemic lupus erythematosus
(SLE), and familial chilblain lupus (FCL).(3,13,14,20) In
each of these diseases, TREX1 mutations usually decrease
or abolish exonuclease function. AGS mimics a congenital
viral infection of the brain and typically manifests as
a neurodevelopmental disorder in early infancy. As the
extra-neurological findings in AGS overlap with SLE,
AGS has been proposed as a genetic model of systemic
autoimmunity.(14) RVCL though does not clinically or
pathologically resemble an autoimmune disease but rather
a premature degeneration of the microvasculature.(26)
Most studies have focused on the exonuclease activity
of TREX1, for which the carboxy-terminus is not necessary. Recently, it has been shown that the carboxyterminus plays a role in suppressing glycan-induced
inflammation, a function that is lost by the frame-shift
mutations of RVCL.(8) More recently, mice carrying a
common RVCL frame-shift mutation have developed
autoantibodies although this is infrequently observed in
patients with RVCL.(15,26) However, the mechanism by
which this mislocalized but enzymatically active exonuclease results in a systemic vasculopathy remains
elusive.
Although TREX1 transcripts have been identified at
the RNA level in all tissues examined, the endogenous
expression of the protein has not been studied.(17) Given
the burden of the neurological disease in RVCL, we
evaluated the expression of TREX1 in human brain tissue using a rabbit polyclonal antibody (pAb) we produced.
With the use of immunohistochemical and immunofluorescent staining, we sought to identify the specific cell
types expressing TREX1 in the brain for insight into
the relationship between this exonuclease and the
microvasculature.

MATERIALS AND METHODS
Antibody production
As insufficient amounts of recombinant wild-type TREX1
could be recovered by us (unpublished) or others,(10,16,17)
recombinant V235fs mutant TREX1 was produced in E.
coli (detailed in the Supplementary Methods).
Antibody purification
The rabbit pAb to TREX1 was purified by precipitation
with saturated ammonium sulfate for use in WB analyses.
For immunofluorescence and immunohistochemical staining, the pAb was further purified by antigen affinity to
the recombinant E. coli immunogen (V235fs). Details are
supplied in the Supplementary Methods. The purified Ab
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Figure 1. Expression and detection of TREX1 proteins. A. The rabbit
anti-TREX1 Ab detects the recombinant TREX1 (rV235fs) as well as E.
coli heat shock protein 70 (Hsp70) in the immunogen on Western blot
(WB). B. On strips from the same WB, the anti-TREX1 Ab detects a
band at ~75 kDa in 293T cells (left panel) that is eliminated after preincubation with E. coli Hsp70. The bands at 37 and 32 kDa are
unchanged. C. A schematic of TREX1 transcript variants with solid red
bar for coding sequence, open red bar for untranslated regions, and red
line for intron. Transcript variant 1 retains the intron and encodes a
longer N-terminus. D. 293T cells transiently transfected with fluorescent

protein (FP)-tagged wild-type TREX1 (green) for isoforms-A (left panel)
and B (right panel). Nuclei are counterstained with TO-PRO-3 (blue).
Scale bar represents 28 μm. E. Representative WB of TREX1 from 293T
cells transfected with wild-type TREX1 isoforms-B (lane 1) and A (lane
2) for positive controls and HeLa cells transfected with TREX1 siRNA 1
(lanes 3 and 7) or 2 (lanes 4 and 8), negative control (NC1, lanes 5 and 9)
as well as an untreated control (lane 6). Cell lysates were evaluated at
48 (lanes 3–5) and 72 (lanes 7–9) h after transfection with siRNA.
Membrane was stripped and reprobed with anti-β-actin Ab as a loading
control.

preparations were electrophoresed on a Tris-glycine gel
and stained with Coomassie Blue to assess purity.
Preincubation of 1 μg/ml Ab with 10 μg/ml recombinant

E. coli heat shock protein 70 (Hsp70, also known as DnaK;
ProSpec, Ness Ziona, Israel) was accomplished at 4°C for
3 h with rotation.
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Plasmid construct, cell culture, and transfection

Immunofluorescence

The cDNA for human TREX1 was obtained from OriGene
Technologies (Rockville, MD) and variants 1 and 4
(Fig. 1) were cloned into the EcoR1/XbaI sites in the
pSBC expression vector, with and without an aminoterminal fluorescent protein (FP) tag. The frame-shift
mutation was introduced by site-directed mutagenesis
(QuikChange II Site-Directed Mutagenesis Kit; Agilent,
Santa Clara, CA).
The TREX1-specific siRNAs were targeted to the following
sequences, 5′-GGTTGTGACAGCAGATGGTCTTGGCT-3′
(siRNA1) and 5′-CAAGGAAGAGCTACAGC CTAGGC
AG-3′ (siRNA2). A universal negative control (NC1) was
obtained from Integrated DNA Technologies (Coralville, IA).
Details on transfection of 293T cells with plasmid expression vectors and HeLa cells with siRNA can be found in
the Supplementary Methods.
EBV transformed B lymphocytes were generated from
normal controls and subjects carrying the RVCL
mutation.(8,24)

293T cells were plated in 6-well chamber slides 24 h prior
to transfection. Cells were transiently transfected
(TransIT-293 transfection reagent; Mirus, Madison, WI)
for 24 h before being fixed and permeabilized with acetone.
Nuclei were counterstained with TO-PRO-3 (Life
Technologies, Grand Island, NY). Cells were then visualized with a confocal microscope (Zeiss LSM510 META
Laser Scanning Confocal Microscope; Carl Zeiss
Microscopy, Jena, Germany).
Frozen sections were fixed with 95% ethanol, 5% glacial
acetic acid for 30 min and then washed with PBS. Formalinfixed, paraffin-embedded (FFPE) sections were hydrated
sequentially with 5-min washes in xylene x 2, 95% ethanol
x 2, 70% ethanol, 50% ethanol, and PBS. Antigen retrieval
was performed in a pressure cooker with 1 mM EDTA pH
8 buffer for 2 min. After 3 PBS washes, the slides were
blocked with avidin and biotin solutions (Vector Laboratories,
Burlingame, CA). Slides were incubated with blocking buffer
(10% serum diluted in PBS with 1% BSA) for 30 min and
then with the primary Ab diluted in blocking buffer overnight at 4°C in a humidified chamber. Human serum was
included in all blocking buffers to reduce non-specific background. After PBS washes, the slides were incubated for 1
h with an appropriate fluorophore-conjugated secondary Ab
diluted in blocking buffer. The slides were washed with PBS
and then incubated with TO-PRO-3 diluted 1:200 in PBS
for 30 min. After PBS washes, coverslips were placed on
slides using VectaMount Hard Set Fluorescent Mounting
Media (Vector Laboratories) before visualization by confocal
microscopy.
The primary Abs used included the rabbit pAb to TREX1
(1:200, 1 μg/ml), mouse monoclonal anti-CD68 (KP1 at
1:200; Abcam, Cambridge, MA), mouse monoclonal antiMHC II (CR3/43 to HLA-DR-DP-DQ at 1:200; Abcam),
mouse monoclonal anti-alpha smooth muscle actin (1A4
at 1:50; Abcam), mouse monoclonal anti-glial fibrillary
acidic protein (GFAP; 1:200; Sigma) and biotinylated ricinus
communis agglutinin I (RCA-1; Vector Laboratories). For
slides stained with biotinylated RCA-1, blocking buffer
was excluded and the primary Ab was diluted 1:10,000 in
PBS and the FITC-Avidin secondary was diluted 1:200 in
PBS. Secondary Abs alone were used as negative
controls.

PCR and reverse transcription (RT)-PCR
Genomic DNA (gDNA) and RNA were obtained from
cell lines using the Wizard Genomic DNA purification
kit (Promega, Madison, WI) and RNeasy Mini Kit (Qiagen,
Valencia, CA), respectively. RNA was treated with DNase
I (Invitrogen) to remove DNA contamination. RNA was
amplified with the Invitrogen SuperScript One-Step RT-PCR
with Platinum Taq. The gDNA and RNA were amplified
with Platinum Taq (Invitrogen). The forward and reverse
primers to detect TREX1 transcript variants 1 and 4 were
5′-AGCGAGAGCCGCGGGAGAGTG-3′
and
5′-CACACGCGGTGGTGGAGGAA-3′. The forward and
reverse primers to amplify TREX1 transcript variant 1
were
5′-GCCTGCTACGGTGAGTGTGGC-3′
and
5′-CTGCTGAGCCTGGAGAGGAGC-3′.
PCR
and
RT-PCR were performed at 50°C for 30 min to allow
reverse transcription and followed by 35 cycles at 94°C
for 15 s, 60°C for 30 s and 72°C for 1 min. The resulting
products were run on an agarose gel.
Western blotting
Briefly, cell lysates were electrophoresed on 12% Tris-glycine
gels (Life Technologies, Carlsbad, CA), transferred to a
nitrocellulose membrane and blocked overnight in 5% nonfat dry milk in Tris-Buffered Saline and Tween 20 (TBS-T).
The membrane was incubated with the primary Ab, rabbit
pAb to TREX1 diluted 1:1000 or mouse monoclonal antiβ-actin Ab (Sigma Aldrich, St. Louis, MO) diluted 1:5000
in 5% non-fat dry milk. After washes with TBS-T, the
membrane was incubated with the appropriate horseradish
peroxidase (HRP)-conjugated secondary Ab followed by
additional washes with TBS-T. The Western blots (WB)
were developed with West Pico SuperSignal (Thermo Fisher
Scientific, Waltham, MA). The protein bands from WB
were scanned and quantified using ImageJ (NIH, Bethesda,
MD).

Immunohistochemistry
FFPE sections underwent hydration, antigen retrieval, avidin–biotin blocking, and incubation with blocking buffer
and primary and secondary Abs as described above.
Endogenous peroxidase was quenched with a 3% solution
of hydrogen peroxidase for 30 min prior to antigen retrieval.
For slides stained with rabbit pAb to the ionized calciumbinding adapter molecule 1 (Iba1; Wako, Richmond, VA)
diluted 1:1000 in blocking buffer, the secondary was a
biotinylated anti-rabbit IgG (Jackson ImmunoResearch
Laboratories, West Grove, PA). The signal on these slides
was amplified with the Avidin–Biotin–HRP complex (ABC;
Vector Laboratories) before being developed with the
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3,3′-diaminobenzidine tetrachloride (DAB) substrate
(Vector Laboratories) as the chromogen. For slides stained
with rabbit pAb to TREX1 (diluted 1:200 in blocking
buffer), the secondary was a peroxidase-conjugated antirabbit IgG (Jackson ImmunoResearch Laboratories). These
slides were developed with DAB. Coverslips were mounted
with VectaMount Permanent Mounting Media (Vector
Laboratories).
Experimental design
Serial sections stained with TREX1 or Iba1 were blinded
and three sets of 10 consecutive images were obtained
with a 40X objective for each brain region. Images were
taken from the cerebral white and gray matter, basal ganglia, thalamus, hippocampus, and cerebellar molecular
layer and white matter. All cell counts were confined to
undamaged tissue. The total number of cells expressing
TREX1 and Iba1 were counted for each image. A cell
was considered to be within a given image only if the
nucleus was present to prevent counts in two consecutive
images. The average of all three sets was used for the
data analysis. For each individual, the percent of TREX1+
microglia was calculated relative to the total number of
Iba1+ cells in that section. The percent of Iba1+ cells in
the white matter of the cerebral cortex was calculated
relative to the total number of Iba1+ cells within the white
and gray matter of that section for each subject. Similarly,
the percent of TREX1+ cells in the white matter is reported
relative to the total number of TREX1+ cells on that
section.
Study subjects
Tissue sections from the frontal lobe, occipital lobe, basal
ganglia, hippocampus, thalamus, and cerebellum were
obtained from all subjects except one case of RVCL
(Table 1). In cases with RVCL or other neurological diseases, additional sections were available. The six normal
controls were screened for the absence of neuropathology
on hematoxylin and eosin (H&E) staining.
The five RVCL cases were selected based on the availability of tissue sections for analysis. All had their diagnoses
well established at the time of death, including a known
family history, a frame-shift mutation in TREX1 and clinical manifestations of the characteristic white matter lesions
and retinal vasculopathy.(26) Except for one case of RVCL
from the Cleveland Clinic with the T249fs mutation, other
subjects carried the V235fs mutation. They were from two
unrelated individuals who underwent complete autopsies
by the Department of Pathology and Immunology at
Washington University School of Medicine. Tissue sections
from all brain regions were available for four of the five
RVCL cases. In one of the cases only the frontal lobe and
additional sections from the cerebral cortex were
available.(12)
At least two cases with radiation necrosis, multiple sclerosis, hemorrhagic stroke, and ischemic stroke were selected
based on a search of the pathology database at the
Washington University School of Medicine. A
810

Table 1. Clinical and pathological features of cases and controls
Normal
Controls

Ischemic
Stroke

RVCL

n

6

5*

4

Age at death
(years)
Female
gender
Brain weight
(g)
Post-mortem
interval (h)

60.3 ± 5.2
(range 52-66)
3 (50%)

56.0 ± 4.2
(range 50-60)
2 (40%)

53.3 ± 2.5
(range 52-57)
2 (50%)

1251 ± 107

1128 ± 181†

1277 ± 93

37.2 ± 32.6

6.1 ± 2.5†

20.5 ± 13.8

RVCL, Retinal Vasculopathy with Cerebral Encephalopathy.
*
Tissue from all brain sections unavailable for one subject.
†
Data available on four of the five RVCL cases.

neuropathologist (GRK) selected the normal controls and
cases. All tissue sections were de-identified prior to staining. The clinical demographics and pathological details
of all subjects are presented in Table 1.
Statistical analysis
In WB analyses, levels of TREX1 were adjusted relative
to β-actin levels and are reported as mean ± standard
deviation (SD). For quantification of immunohistochemical
staining (detailed in Experimental design above), all data
are presented as mean ± standard error of the mean (SEM).
Statistical analyses were performed using the Mann–
Whitney U test.

RESULTS
Characterization of antibody
To evaluate the specificity of our rabbit pAb to recombinant TREX1, we performed WB analyses. Western
blotting of the recombinant E. coli protein used to
immunize the rabbits detected a band for the recombinant V235fs TREX1 and a second band at ~70 kDa
(Fig. 1A). Mass spectroscopy identified this latter band
as E. coli heat shock protein 70 (Hsp70), which has been
reported to co-purify with some recombinant proteins.(23)
Western blots for endogenous TREX1 in 293T cells also
identified a cross-reacting protein at ~70 kDa which was
blocked by preincubation of the pAb to TREX1 with
recombinant E. coli Hsp70 (Fig. 1B). In lysates from
293T cells transfected with YFP-tagged TREX1 (wildtype and V235fs), the rabbit anti-TREX1 Ab detects bands
of the same mol wt as anti-YFP (not shown).
Two major bands at 37 and 32 kDa were detected in
293T cells (Fig. 1B) along with an unidentified light band
at 27 kDa, intermittently seen on WBs, which may be a
fragment of TREX1 as reported previously.(17) The band
at 32 kDa corresponds to TREX1 transcript variant 4
(NM_033629.4), encoding isoform-B (NP_338599.1, 314 amino
Brain Pathology 28 (2018) 806–821
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acids) of the wild-type protein (Fig. 1C). The band at 37
kDa likely represents TREX1 transcript variant 1
(NM_016381.5) encoding isoform-A (NP_057465.1, 369 amino
acids), which is included in NCBI databases. Isoform-A retains
the intron encoding a longer amino-terminus but is otherwise
identical to isoform-B with respect to the amino acid sequence
and localization (Fig. 1D). Although small amounts of the
unspliced transcript encoding isoform-A have been found
in human tissues (18), expression of the protein has not been
reported in the literature. Both bands were observed however
in human monocyte-derived macrophages from peripheral
blood and four other human cell lines tested, namely HeLa,
THP-1, U937, and Jurkat (not shown).
We next asked if the band at 37 kDa is indeed isoformA of TREX1. The 37- and 32-kDa bands are endogenously
expressed in HeLa cells and align with the recombinant
wild-type TREX1 isoforms-A and B transiently expressed
in 293T cells, respectively (Fig. 1E, lanes 1 and 2). The
plasmid encoding the longer isoform-A also produces
isoform-B (lane 2, Fig. 1E), likely from use of the downstream start site of transcript variant 4.
HeLa cells transfected with TREX1 siRNA (targeting
sequences shared by both transcript variants) were then
analyzed for changes in protein expression at 48 and 72 h.
Although the levels of TREX1 isoform-B (32-kDa band) were
found to be decreased at both time points, there was only
a moderate decrease in the 37-kDa band at 72 h (Fig. 1E).
As the 37-kDa band showed a greater decrease at 72 h,
that time point was used for subsequent studies. Three independent experiments showed that at 72 h, compared to the
negative control siRNA, the 32-kDa band was substantially
reduced (18–35% of control), while the 37-kDa band was
only moderately reduced (53–63% of control) by TREX1specific siRNA (Supplementary Fig. 1A).
The presence of messenger RNA (mRNA) from both
transcript variants was also studied in 293T, HeLa and
EBV transformed B lymphocytes from normal controls
and carriers of the RVCL frame-shift mutation
(Supplementary Fig. 1B). Primers designed to anneal
outside the retained intron in transcript variant 1 allowed
differentiation of the two transcripts based on size. From
RT-PCR of total mRNA from 293T cells, we observed
two bands corresponding to transcripts 1 and 4 of TREX1.
On the other hand, HeLa cells and the EBV transformed
lymphocytes had one major band corresponding to transcript 4 and a faint band corresponding to transcript 1.
The PCR, run in parallel on the mRNA from both cell
lines, showed no product even though genomic DNA
was able to amplify a band the same size as transcript
1. Thus, genomic DNA contamination was not responsible
for the band attributed to transcript 1. To further verify
the presence of transcript variant 1 in the cell lines
examined, primers were designed to specifically amplify
it. In all the cell lines examined, transcript variant 1
was detected by RT-PCR of mRNA but not PCR, which
would amplify genomic DNA (Supplementary Fig. 1C).
Thus, transcript variant 1 is expressed at the mRNA
level and these results indicate that our Ab is detecting
TREX1 isoform-A.

TREX1 in Human Brain Tissue

Endogenous expression of TREX1 frame-shift
mutants associated with RVCL
Using EBV transformed B-lymphocytes from normal controls
and carriers heterozygous for the V235fs mutant, the endogenous expression of TREX1 was evaluated by WB (Fig. 2).
293T cells transfected with both isoforms of wild-type TREX1
and the frame-shift mutants were included as positive controls
(Fig. 2A, lanes 1–2 and 9–10). The proteins from transcript
variant 4 (corresponding to isoform-B) were detected at their
expected molecular weight (32 kDa and 25 kDa for wildtype and V235fs mutant, respectively; lanes 1 and 2). As
noted above, the wild-type isoform-A was detected at 37
kDa but the transfected cells also produced similar amounts
of isoform-B (32 kDa; lane 9). The RVCL mutation in isoformA, V290fs, should be detected at ~30 kDa. However, the
transfected cell lysates produced a smear, probably due to
degradation, and a 25-kDa band corresponding to the V235fs
mutant (lane 10).
Endogenous levels of TREX1 were observed in the EBV
transformed B lymphocytes from normal controls and heterozygous carriers of the RVCL mutation (Fig. 2A, lanes
3–8). For each subject, 1 x 106 cell equivalents were loaded
to detect the protein (with a 1-min exposure), though transfected protein was detected in ~3 x 105 cell equivalents. In
contrast, β-actin levels were easily detected (with a 2 s
exposure) for each subject but not for the transfected cell
lysates, which indicates that TREX1 is expressed endogenously at low levels. Wild-type TREX1 was observed in all,
regardless of genotype. However, the amount of wild-type
isoform-B in carriers of the frame-shift mutation was about
60% (range 41–82%; 50% expected) of that present in normal
controls (Fig. 2B). The levels of the 37-kDa band, likely
representing TREX1 isoform-A, did not show the same variability with respect to genotype. In addition, the 37-kDa
band did not have a consistent pattern with respect to the
32-kDa band; sometimes both were detected in equal amounts
while at other times one or the other was more highly
expressed.
As expected, the endogenous V235fs mutant was
observed only in carriers with the RVCL mutation
(Fig. 2A, lanes 4, 6, and 8). The expression of the V235fs
mutant was ~27% (range 13–44%) of wild-type TREX1
isoform-B in normal controls (Fig. 2B), less than the
50% expected in heterozygous carriers. The V290fs, which
was poorly detected even in transfected cell lysates, was
not detected in any of the carriers. This may be because
the V290fs is not stable when expressed (similar to the
transfected protein) or is expressed below the level of
detection.

Optimization of rabbit pAb to TREX1 for
staining in human brain tissue
We next investigated the utility of the rabbit pAb for staining of tissue sections from human brain. Although the serum
from the final bleed was satisfactorily employed for WB, it
resulted in a high background when staining tissue. However,
a two-step process of purifying the IgG fraction from the
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Figure 2. Endogenous expression of TREX1 in normal controls and
heterozygous carriers of the V235fs mutant. A. Representative Western
blot of transfected TREX1 in 293T cells (lanes 1–2, 9–10) and
untransfected EBV transformed lymphocytes from normal controls and
RVCL mutation carriers. The transfected protein is detected for both
isoforms of wild-type (WT, lanes 1 and 9) and the frame-shift mutant of
isoform-B (V235fs, lane 2). The frame-shift mutant of isoform-A (V290fs,
lane 10) is not well seen. Both the wild-type and frame-shift mutant of
isoform-A also produce the smaller isoform-B (*). Endogenous WT
TREX1 is detected in all EBV transformed lymphocytes. The 37 kDa
band represents TREX1 isoform-A (lanes 3–8). The V235fs mutant is

detected in cell lines derived from heterozygous carriers of the mutation
(lanes 4, 6, and 8) but not in normal controls (lanes 3, 5, and 7).
Endogenous expression of the V290fs mutant is not detected.
Membrane was stripped and reprobed with anti-β-actin as a loading
control. B. The expression of TREX1 protein was normalized to a β-actin
loading control. For each group, Control WT, Carrier WT and Carrier
V235fs, data are shown for the 3 individuals analyzed followed by the
average for that group. TREX1 levels are given relative to the average of
WT in the 3 normal controls (Average Control), which was arbitrarily set
to 1.0. Data are presented as mean ± SD and represent 8 independent
samples.

saturated ammonium sulfate precipitation over an antigenaffinity column yielded an Ab preparation with minimal
background on tissue staining. This Ab was used for all
immunofluorescence and immunohistochemistry studies.
In 293T cells transfected with FP-tagged TREX1, the
Ab only stained transfected cells but not untransfected

cells (Fig. 3A). In order to verify that the staining was
not due to the cross-reacting band observed at ~70 kDa
on WB, we stained sections with the Ab alone and Ab
pre-incubated with E. coli Hsp70 (Fig. 3B). Equivalent
staining was observed for both indicating that the Ab
preparation used was specific for TREX1. No staining
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Figure 3. Specificity of rabbit pAb to TREX1. A. Immunofluorescent
staining of 293T cells transfected with fluorescent protein-tagged wild-type
TREX1 (FP-TREX, green) using the rabbit pAb to TREX1 (red) shows that
the signals overlap (yellow). Scale bar represents 28 μm. B.
Immunohistochemical staining of human brain tissue with rabbit pAb to

TREX1 in Human Brain Tissue

TREX1 alone (left panel) and after pre-incubation of the Ab with E. coli heat
shock protein 70 (Hsp70, right panel). Scale bar represents 100 μm. C.
Immunohistochemical staining of human brain tissue with secondary Ab
alone (left panel) or rabbit pAb to TREX1 (right panel). Scale bar represents
40 μm.
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Figure 4. TREX1 positive cells are microglia and/or macrophages. A.
Dual staining of frozen tissue from a case of RVCL with anti-MHC II
(top panel, green) and anti-CD68 (bottom panel, green), microglial
markers, and anti-TREX1 (red). Nuclei are counterstained with TOPRO-3 (blue). Scale bar represents 28 μm. B. Two examples (upper
and lower panels) of dual staining of formalin-fixed, paraffin-embedded
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human brain tissue from a normal control with RCA-1 (left panel,
green), a microglial/macrophage and endothelial cell marker, and antiTREX1 (red). Nuclei are counterstained with TO-PRO-3 (blue). Some
cells stained with RCA-1 but not TREX1 are endothelial cells based on
their morphology. Scale bars represent 28 μm on top panel and 14 μm
on bottom panel.
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was observed in tissue sections stained with secondary
Ab alone as a negative control (Fig. 3C). These data demonstrate the specificity of the Ab in staining for TREX1.

TREX1 expression in human brain tissue is
restricted to a subset of microglia and
macrophages
We next asked which cells express TREX1 in human
brain. Although we had hypothesized that TREX1 would
be expressed by endothelial cells given the vasculopathy
observed in RVCL, immunohistochemical staining demonstrated that the protein was in glial cells. Frozen
sections from autopsy material obtained from a patient
with RVCL were used for immunofluorescent dual-staining with several glial markers. Based on the morphology
of the TREX1+ cells, astrocytes or microglia were the
most likely candidates. Dual staining with GFAP, an
astrocyte marker, demonstrated no overlap with the cells
stained for TREX1 (Supplementary Fig. 2). CD68 and
MHC II, markers for microglia and macrophages, colocalized with all TREX1+ cells (Fig. 4A). In almost all
cases, the TREX1+ cells were likely to be microglia as
they had the typical ramified morphology and were found
within the parenchyma. While all TREX1+ cells were
identified by these markers, not all microglia and macrophages stained positive for TREX1.
To determine if TREX1+ cells are microglia in brain
tissue from normal controls, we performed immunofluorescent dual-staining on FFPE autopsy tissue. Although
CD68 and MHC II did not stain well on FFPE tissue,
RCA-1 did. RCA-1 is a lectin that serves as a marker
for microglial/macrophages and endothelial cells, which
can be differentiated based on morphology. Similar to
the findings observed in frozen sections, the TREX1+
cells were predominantly microglia (Fig. 4B), but not all
microglia were TREX1+. Some TREX1+ cells around the
vasculature had a rounded morphology, which may be
representative of perivascular macrophages (Fig. 4B, bottom panel). Thus, TREX1 is a marker for a subset of
microglia and perivascular macrophages in human brain
tissue.

Expression of TREX1 in human brain tissue
from normal controls
To determine the distribution of TREX1+ cells and the
proportion of microglia they represent in the normal human
brain, we performed immunohistochemical staining on
serial sections using TREX1 and Iba1, a marker for microglia and macrophages. Using the Abs in parallel allowed
us to control for variability in staining due to fixation
and the age of the sections as well as control for differences in cellular density. Absolute cell counts are provided
in Supplementary Fig. 3.
The expression of TREX1 varied considerably among
the brain regions examined (Fig. 5A). The percent of
TREX1 expressing microglia (mean of TREX1+ cell count/
Iba1+ cell count within the specified brain region for all
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individuals in the group) was highest in the basal ganglia
(49.8 ± 9.9% of microglia) followed by the gray matter of
the cerebral cortex. Unlike the gray matter, fewer TREX1+
microglia were identified in the white matter of the cerebral cortex (22.8 ± 5.1% of microglia in gray matter vs.
5.5 ± 1.9% of microglia in white matter, p ≤ 0.01). Although
the microglia were equally distributed in the gray and
white matter of the cerebral cortex (Iba1 stain, 54.8 ±
2.4% in white matter), TREX1+ microglia were observed
less frequently in the white matter (TREX1 stain, 21.6 ±
5.5% in white matter; Fig. 5B-D). As such, the difference
in the distribution of TREX1+ cells between the gray and
white matter is not due to a difference in the distribution
of microglia overall. In addition, while the Iba1+ cells
were uniformly spread throughout the parenchyma of the
gray and white matter, TREX1+ cells were not. The TREX1+
microglia in the cerebral cortex were often closely associated with the microvasculature, particularly in the gray
matter (Fig. 5F). These TREX1+ microglia were either flush
against the vessel or had foot processes extending to the
vessel perimeter. Dual staining with anti-TREX1 and antialpha smooth muscle actin, a marker for vascular smooth
muscle cells and pericytes, showed no co-localization (not
shown).
In the hippocampus and the deep gray matter of the
thalamus and basal ganglia, the TREX1+ cells were scattered throughout the parenchyma (Supplementary Fig. 4).
No differences were observed in the distribution of TREX1+
microglia between the hippocampus, subiculum and parahippocampus. In the basal ganglia, the TREX1+ microglia
were noted in both the white matter tracts (pencil fibers
of Wilson) as well as the surrounding gray matter. In the
cerebellum, the TREX1+ cells were present in the molecular
layer and white matter. TREX1 expressing microglia were
associated with the dentate nucleus in the cerebellum of
all normal controls (n=5, dentate nucleus not included on
section from 1 subject). Except for the cerebral cortical
gray matter and basal ganglia, the percent of microglia
expressing TREX1 was less than 15% in the regions
quantified.

Expression of TREX1 in undamaged brain
tissue from subjects with RVCL
We next studied the expression of TREX1 in the brain
from cases of RVCL in histologically normal appearing
tissue. Although there was variability in the percent of
TREX1 expressing cells in the brain regions examined,
which was also noted in normal controls, there were differences between the two groups (Fig. 5). The most striking
distinction was the increased expression of TREX1 in the
white matter of the cerebral cortex from brain tissue of
RVCL cases (5.5 ±1.9% of Iba1+ microglia in normal controls vs. 38.9 ± 5.8% in RVCL, p ≤ 0.01; Fig. 5A-E). In
addition, TREX1 expressing cells in the gray matter of
RVCL cases were decreased compared to normal controls
(22.7 ± 5.1% in controls vs. 11.8 ± 3.1% in RVCL, p ≤
0.02). Although the proportion of Iba1+ microglia in the
white matter was similar to that of normal controls (54.8
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Figure 5. Distribution of TREX1 expressing cells. A. Distribution of
TREX1+ microglia by brain regions in normal controls and cases of RVCL
and ischemic stroke. The proportion of TREX1 cells is shown relative to
the mean number of microglia (Iba1 stained cells) for specific areas of the
brain in normal controls (blue bars) and cases with RVCL (red bars) or
ischemic stroke (green bars). Sections quantified in RVCL and ischemic
stroke were taken from undamaged tissue. The number of tissue
sections included for each observation is noted above the appropriate
column. White matter (WM); Gray matter (GM). Data are presented as
mean ± SEM. B-C. Distribution of TREX1 and Iba1 staining in the cerebral
cortex of normal controls and cases of RVCL and ischemic stroke. The
proportion of Iba1 (E) or TREX1 (F) cells located in the white matter for the
frontal lobe, occipital lobe and the cerebral cortex in normal controls (blue
bars) and cases with RVCL (red bars) or ischemic stroke (green bars). The
values represent the mean among each group for cell counts in the white

816

matter divided by the total cell counts in the white and gray matter for the
specified region. Sections quantified in RVCL and ischemic stroke were
taken from undamaged tissue. The cerebral cortex includes sections
from the frontal, parietal, temporal and occipital lobes. The number of
tissue sections included for each observation is noted above each
column. Data are presented as mean ± SEM. D-E. Immunohistochemical
staining of a normal control and subject with RVCL with Iba1 (left panels)
and TREX1 (right panels) in the gray (top panels) and white matter (bottom
panels). For RVCL, undamaged brain tissue is shown. Staining for Iba1
and TREX1 is developed with DAB (brown). Nuclei are counterstained
with hematoxylin (blue). Scale bars represent 100 μm. F. Representative
immunohistochemical staining of normal control gray matter with TREX1
microglia (DAB, brown) in association with microvasculature (arrows).
Nuclei are counterstained with hematoxylin (blue). Scale bar represents
40 μm.
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± 2.4% in controls vs. 53.6 ± 1.7% in RVCL, p = n.s.;
Fig. 5B), there was a marked increase in the proportion
of TREX1+ cells in the white matter (21.6 ± 5.5% in controls vs. 83.5 ± 2.3% in RVCL, p ≤ 0.01; Fig. 5C). Thus,
compared to normal controls, the TREX1+ cells are
increased in the white matter and decreased in the gray
matter of RVCL cases, even though the distribution of
microglia between the gray and white matter is similar
in both groups. The increased expression of TREX1 in
the white matter is also observed in the cerebellum of
RVCL cases compared with normal controls (Fig. 5A).
Another difference between RVCL and normal control
brain tissue was the distribution of TREX1+ cells within the
white matter. In RVCL (within histologically normal white
matter), there were areas without TREX1+ cells while other
regions on the same tissue section had clusters of TREX1+
cells. This is in contrast to normal controls where the TREX1
expressing cells were more uniformly distributed.
With the exception of the white matter regions, the
expression of TREX1 was reduced or similar to that seen
in normal controls in other brain regions (Fig. 5A,
Supplementary Fig. 3). Within the thalamus, the TREX1+
microglia could be observed scattered in both the gray
and white matter. Similarly, in the basal ganglia the TREX1+
cells were located within the white matter tracts (pencil
fibers of Wilson) and in the adjacent gray matter. In some
cases, the pencil fibers of Wilson showed TREX1+ cells
with a rounded morphology, similar to macrophages, even
though no lesions were observed in the adjacent tissue
on the section. TREX1+ cells were rarely found in the
hippocampus. In the cerebellum, TREX1 was primarily
noted in the white matter while the molecular layer had
occasional scattered TREX1+ microglia. The dentate nucleus
was only included in a tissue section from 1 case with
RVCL making it difficult to compare to the findings in
normal controls. Except for the white matter and basal
ganglia, TREX1+ microglia represent less than ~15% of
all microglia in other regions, similar to our observations
in normal controls.

Expression of TREX1 in ischemic lesions
We next evaluated the expression of TREX1 in the white
matter lesions of RVCL cases. The neuropathological findings observed in RVCL consist of scattered areas of ischemic
necrosis in the white matter associated with wall thickening
and stenosis of the small blood vessels. (26,12) Given that
RVCL results in occlusion or loss of small blood vessels,
we also compared our findings to cases of ischemic stroke
as that is also a result of disruption in blood flow. In
ischemic lesions, there was a distinct pattern in most cases
(11 sections from five subjects with RVCL and 13 sections
from four subjects with stroke). In close proximity to large
necrotic areas, often with calcifications, few TREX1+ cells
were present. In many cases, only an empty cavity surrounded by a variable necrotic zone remained. Bordering
the lesions, a subset of the round, foamy cells expressed
TREX1. Dual staining with RCA-1 and TREX1 demonstrated co-localization (Supplementary Fig. 5). The cell
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morphology in these cases is similar to that of activated,
ameboid microglia or infiltrating macrophages, cell types
that cannot be distinguished in human brain tissue sections with current markers. Moving away from the lesion,
the TREX1+ cells gradually change their morphology to
a more ramified appearing microglia (Fig. 6A, bottom
panel). In ischemic stroke cases, these TREX1+ cells are
observed in distinct tracts, usually within the adjoining
white matter (Fig. 6B). Other lesions had none or faintly
stained TREX1+ cells (five sections from four subjects with
RVCL and two sections from one subject with stroke).
The staining was unchanged after pre-incubation of the
Ab with Hsp70 (not shown).
To determine if the differences noted between normal
controls and RVCL were applicable to ischemic injury in
general or were specific to RVCL, we also quantified the
expression of TREX1 in sections consisting of undamaged
brain tissue from cases with ischemic stroke. All of the
groups studied demonstrated variability between different
brain regions with respect to the percent of microglia
expressing TREX1 (Fig. 5A). In general, there was a greater
proportion of TREX1+ microglia in all brain regions with
stroke compared to normal controls and most regions
examined in RVCL cases. This increase is likely in response
to the ischemic injury, as it was not observed in other
neuropathologies screened (multiple sclerosis, radiation
necrosis and brain tumors; not shown). Only in the white
matter of the cerebral cortex did RVCL cases have the
highest expression of TREX1 (38.9 ± 5.8% of Iba1+ microglia for RVCL vs. 14.5 ± 3.1% for ischemic stroke, p ≤
0.01). Similar to normal controls and RVCL cases, microglia
were evenly distributed between the white and gray matter
in ischemic stroke (55.0 ± 1.3% of Iba1+ cells in white
matter, Fig. 5B). In contrast, the proportion of TREX1+
cells in the white matter was increased compared to normal controls but not as highly as in RVCL (40.4 ± 6.8%
in ischemic stroke, Fig. 5C).
More TREX1+ microglia were observed in ischemic stroke
compared with normal controls for all brain regions. In
the cerebellum, an association of TREX1+ cells with the
dentate nucleus was observed in all stroke cases (n=4),
similar to our findings in normal controls. However, despite
the increased expression of TREX1 in ischemic stroke,
these cells represent less than 30% of microglia in all
brain regions examined, with the exception of the basal
ganglia (77.7 ± 6.8% of TREX1+ microglia).

DISCUSSION
We present here the development and characterization of
a specific rabbit pAb to TREX1 that detects this intracellular protein by WB and tissue staining. Although endogenous TREX1 protein from cell lysates has been observed
by WB,(8,25) our study is the only one to detect TREX1
isoform-A (37 kDa) and we confirmed the endogenous
expression of the frame-shift mutants associated with RVCL.
We also demonstrate the expression of the protein in human
brain tissue for the first time. Further, dual staining
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Figure 6. Immunohistochemical staining in white matter lesions with
anti-TREX1. A. Staining for Iba1 and TREX1 in white matter lesions
from cases with RVCL (left) or ischemic stroke (right). Representative
images from chronic lesions are shown (400x magnification) with
each successive image taken from two high-powered fields away.
Staining for Iba1 and TREX1 is developed with DAB (brown). Nuclei

are counterstained with hematoxylin (blue). Scale bar represents 100
μm. B. Panoramic view of the morphological changes in TREX1+ cells
around a chronic lesion in ischemic stroke (right side) and their
tracking in the adjacent white matter (WM) with relative absence of
TREX1+ cells in the gray matter (GM). Similar findings are noted in
RVCL lesions. Scale bar represents 1 mm.

demonstrated that TREX1 is exclusively expressed by a
subset of microglia and macrophages at our level of
detection.
Microglia are the tissue resident macrophages of the
central nervous system (CNS) where they serve multiple
functions.(2,21) During development they prune extra synapses and facilitate the establishment of the vascular network in the CNS.(1,28) They also perform active surveillance
of the surrounding tissue to maintain homeostasis and
respond rapidly to perceived insults such as injury or
pathogens. Although microglia have been implicated in a
number of neurodegenerative diseases including Alzheimer’s
disease, Parkinson’s disease, ischemic stroke and multiple
sclerosis, our understanding of their primary role in the
brain is incomplete. Initially thought to represent a homogenous population, recently the existence of microglial
subsets with specialized functions has been proposed.(7)
Our results, which show the expression of TREX1 is limited to a subset of microglia, strongly support this view.
The variation in expression of TREX1 by brain region
also suggests a specialized physiologic role.

The association of TREX1+ microglia with the microvasculature, particularly notable in normal control gray
matter, suggests a role for these cells in the development
and/or maintenance of vessels within the CNS. While we
had initially hypothesized that TREX1 would be expressed
in endothelial cells, as RVCL is a systemic vasculopathy,
the observation that the protein is most highly expressed
in microglia suggests an alternative that should be considered for any work pursued in the future. Furthermore,
as microglia are limited to the CNS, this may explain,
in part, the prominent vasculopathy affecting the white
matter and retina in RVCL. Less damage in other organs
from this systemic small vessel disease may be attributable
to differences among tissue resident macrophages, more
efficient repair processes or greater biological reserve.
Future studies on tissues of other organs from subjects
with RVCL are needed to determine where TREX1 is
expressed and in which cell types.
Our studies on TREX1 expression in human brain tissue also demonstrate significant increases in the undamaged
cerebral white matter of cases with RVCL compared to
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normal controls and ischemic stroke. The increase of
TREX1+ microglia in all regions of the brain in ischemic
stroke compared to normal controls suggests that this is
a general response to ischemia. As such, the increased
expression of TREX1 in the undamaged white matter of
RVCL may be indicative of wide-spread ongoing injury
that is undetectable histologically. The clusters of TREX1+
microglia in the white matter of RVCL may correlate with
this low-level injury (and possibly exacerbate it). In addition, the sparing of the gray matter in RVCL may explain
why TREX1+ microglia are less frequent there in comparison to ischemic stroke (where gray matter can be
affected). However, it does not account for why TREX1+
microglia are decreased in the cerebral gray matter of
RVCL compared to normal controls.
Another possibility is that the expression of TREX1 in
RVCL cases is not the result of tissue injury but rather
causes the damage. Regions of the brain that are able to
limit the expression of the mutant TREX1 are therefore
spared; though how this is regulated remains unexplained.
In order to differentiate between mutant TREX1 expression causing the white matter damage in RVCL or being
increased as result of injury, an animal model that develops
the clinical manifestations would be valuable.
A role for TREX1 in ischemia is further supported by
our findings in the lesions of RVCL and ischemic stroke.
In most lesions, increased expression of TREX1 was
observed in ameboid microglia and/or infiltrating macrophages. This increase of TREX1+ microglia may be due
to migration toward the infarct to assist in clearance.
These findings are consistent with the known response of
microglial to injury wherein microglia transition to an
ameboid morphology and migrate toward sites of sterile
injury.(9,27) We hypothesize that TREX1 assists in phagocytosis and clearance of necrotic debris in both macrophages
and microglia. Although TREX1 degrades cytosolic DNA
in the cytoplasm, it has not been detected in lysosomal
compartments.(34) However, it is possible that, in the setting of large necrotic lesions, TREX1 becomes involved
in degrading DNA waste and that defects in clearance of
nucleic acids may exacerbate ischemic injury.
Alternatively, TREX1 may serve another function unrelated to its exonuclease activity, such as limiting the inflammatory activation of phagocytes.(22,25) It is possible that
RVCL mutants impair this function, which may worsen
an ischemic insult.
One limitation of our study is that the samples from
patients with RVCL were predominantly from those carrying the V235fs as that is the mutation found in the
families cared for at our institution. However, this mutation is the one most commonly found across the globe
in unrelated individuals, being present in approximately
50% of the families described to date [26 and M.K. Liszewski
and J. P. Atkinson, unpublished]. Thus, it is possible that
the individual mutations may demonstrate differences in
the expression of TREX1. However, that is unlikely as
the clinical manifestations of RVCL are similar across the
various mutations discovered to date (4,32) and the one
case carrying the T249fs mutation demonstrated findings
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that were consistent with what was observed with the
V235fs mutation. Additional studies including brain tissue
from subjects with the other RVCL-associated mutations
will be needed to determine if there is any variability.
Another limitation of our study is that we are only able
to observe TREX1 if it was expressed at levels detectable
by tissue staining. In Western blots we have been able to
detect endogenous TREX1, albeit in large samples, in various different cell types. As such, it is probable that TREX1
is expressed in additional cell types. Regardless, the detection of TREX1 in only a subset of microglia and perivascular macrophages suggests that these cell types are of
particular relevance in future studies of RVCL. Additional
studies are also needed to determine if the expression of
TREX1 in the microglia plays a role in other diseases
associated with mutations in TREX1, such as AGS, SLE
and FCL, or if there are differences in the expression of
TREX1 by organs and/or cell types.
In summary, we generated a highly specific rabbit pAb
that is able to detect endogenous levels of human TREX1
by WB and tissue staining. With this Ab we localized
TREX1 to a subset of microglia in human brain tissue.
Our staining demonstrates an association between these
TREX1+ microglia and the microvasculature in normal,
undamaged tissue. The function of these cells still needs
to be determined but it is possible that the TREX1+ microglia are a specialized subset involved in vessel homeostasis
and/or the response to ischemic injury. The increase in
TREX1 expression in ischemic stroke strongly indicates
that it plays a role in the handling of necrotic debris.
Further studies clarifying this exact relationship of TREX1+
microglia with the microvasculature and with ischemic
lesions should provide insight into how a functional but
mislocalized exonuclease results in the clinical manifestations of RVCL.(8,26)
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SUPPORTING INFORMATION
Additional supporting information may be found online
in the Supporting Information section at the end of the
article.
Figure S1. Expression of TREX1 protein isoforms and transcript variants. A. The level of TREX1 protein was normalized to a β-actin loading control. The level of TREX1 was
expressed relative to the negative control (NC1) which was
arbitrarily set to 1.0. Light and dark blue bars represent
the 37- and 32-kDa bands, respectively. Data, presented
as mean ± SD, are the result of three independent samples. B. Reverse-transcriptase PCR (RT-PCR) of DNase I
treated RNA from 293T (lane 1), HeLa (lane 2) cells, and
EBV-transformed lymphocytes from carriers of the V235fs
mutation (lanes 3 and 5) and controls (lanes 4 and 6). PCR
of DNase I treated RNA serves as negative controls for the
RT-PCR (lanes 7–12). PCR of genomic DNA (gDNA) from
293T (lane 13) and HeLa (lane 14) serve as positive controls
for the PCR reaction. Transcript variants 1 and 4 produce
~600 and 270 base pair products, respectively, with primers that align to regions shared between both transcripts
and surrounding the retained intron in transcript variant
1. C. Same as B with primers designed to detect transcript
variant 1 only as a ~300 base pair product.
Figure S2. TREX1 expressing cells are not astrocytes. Dual
staining of formalin-fixed, paraffin-embedded human brain
tissue from a case of RVCL with anti-glial fibrillary acidic

TREX1 in Human Brain Tissue

protein (GFAP, green), a marker for astrocytes, and antiTREX1 (red). Scale bar represents 21 μm.
Figure S3. Absolute cell counts for Iba1 and TREX1 by brain
region in normal controls and cases of RVCL and ischemic
stroke. The cell counts for Iba1 (A) and TREX1 (B) for specific areas of the brain in normal controls (blue bars), cases
with RVCL (red bars) and cases with ischemic stroke (green
bars). Sections quantified in RVCL and ischemic stroke were
taken from undamaged tissue. The number of tissue sections
included for each observation is noted above each column.
White matter (WM); Gray matter (GM). Data are presented
as mean ± SEM.
Figure S4. Representative immunohistochemical staining for
TREX1 (brown) in normal controls (left panel) and undamaged tissue in RVCL cases (right panel) in specified brain
regions. Nuclei are counterstained with hematoxylin (blue).
Scale bar represents 100 μm.
Figure S5. TREX1 cells are ameboid microglia or infiltrating
peripheral macrophages along the edges of ischemic lesions.
Dual staining of formalin-fixed, paraffin-embedded human
brain tissue from a case of ischemic stroke with RCA-1 (left
panel, green), a microglial/macrophage and endothelial cell
marker, and anti-TREX1 (red). Nuclei are counterstained
with TO-PRO-3 (blue). Scale bar represents 28 μm.
Table S1. Summary of the tissue sections analyzed.
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